Research Peptides
A high-purity research peptide studied in metabolism and mitochondrial research. Available in 10mg and 40mg, with every batch independently tested and dispatched from the UK.
A high-purity research peptide studied in metabolism and mitochondrial research. Available in 10mg and 40mg, with every batch independently tested and dispatched from the UK.
MOTS-c peptide UK is Crown Peptides' mitochondrial-derived 16-amino-acid peptide, available in 10mg and 40mg strengths for laboratory research.
Supplied for laboratory research purposes only — not for human consumption or for medical, veterinary or diagnostic use.
MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within the mitochondrial 12S rRNA region. Its discovery contributed to the concept that mitochondrial DNA can generate short bioactive peptides involved in communication between mitochondria and the rest of the cell.
Also known as: MOTS c, MOTSc, mitochondrial open reading frame of the 12S rRNA type-c.
MOTS-c stands for "mitochondrial open reading frame of the 12S rRNA type-c". It was first described in 2015, when researchers identified a short open reading frame inside the mitochondrial genome that encodes a 16-amino-acid peptide with the sequence MRWQEMGYIFYPRKLR.
That discovery placed MOTS-c among the mitochondrial-derived peptides, a small family that also includes humanin. Most proteins are encoded by nuclear DNA, but these peptides are encoded within the mitochondria's own genome, which is why they interest researchers studying how mitochondria communicate with the rest of the cell.
MOTS-c is often studied alongside other mitochondrial and metabolic research compounds such as NAD+ and SS-31, and it is part of the Metabolic Research Bundle. The MOTS-c research guide covers the studies in plain English.
MOTS-c research centres on mitochondrial signalling, metabolic stress adaptation, glucose utilisation, AMPK-related pathways and communication between mitochondria and the nucleus. In the landmark study that first identified the peptide, MOTS-c prevented diet-induced obesity and insulin resistance in mice through AMPK activation in skeletal muscle (Learn more). Its links to cellular energy metabolism connect it with research on NAD+, making it an important tool in mitochondrial-derived peptide research.
MOTS-c’s best-characterised action runs through AMPK, the enzyme cells use to sense a shortage of energy. The 2015 Cell Metabolism paper that named the peptide, from Changhan Lee and Pinchas Cohen’s group at the University of Southern California, traced an unexpected route. MOTS-c inhibits the folate cycle and the de novo purine synthesis tied to it, which leads to a build-up of AICAR, a natural activator of AMPK. With AMPK switched on, cells reshaped how they used glucose.
Skeletal muscle emerged as the main target tissue. In mice, MOTS-c treatment protected against both age-dependent and high-fat-diet-induced insulin resistance, as well as diet-induced obesity. What makes this so useful to researchers is the direction of travel: a peptide made from the mitochondrial genome adjusting metabolism in the cell around it. That makes MOTS-c a tool for studying how a signal, rather than a nutrient or a coenzyme, can retune energy metabolism in muscle cells and rodent models.
Most of the instructions passing between mitochondria and the nucleus were long thought to flow one way, because the nucleus encodes nearly all mitochondrial proteins. MOTS-c provided evidence for traffic in the opposite direction. In a 2018 Cell Metabolism study, researchers found that under metabolic stress such as glucose restriction, MOTS-c moved into the nucleus, and that this move depended on AMPK.
Once inside, MOTS-c influenced a broad range of nuclear genes, including many carrying antioxidant response elements, and interacted with stress-responsive transcription factors such as NRF2. The authors proposed that the mitochondrial and nuclear genomes co-evolved to regulate each other. For anyone studying mitonuclear communication, MOTS-c is one of the clearest model molecules available. It also gives researchers a practical handle on the question: because the peptide can be added to cells directly, its effects on nuclear gene expression can be followed under controlled stress conditions such as glucose restriction.
Exercise has become one of the liveliest areas of MOTS-c research. A 2021 Nature Communications study reported that exercise raised MOTS-c levels in human skeletal muscle and in the circulation. In mice, MOTS-c enhanced physical performance in young (2 months), middle-aged (12 months) and old (22 months) animals, and intermittent treatment started late in life, at 23.5 months, increased physical capacity and measures of healthspan.
At the cellular level, the same study found that MOTS-c regulated nuclear genes linked to metabolism and protein quality control, shaped skeletal-muscle metabolism and helped myoblasts adapt to metabolic stress. Because its effects overlap with the AMPK signalling that exercise itself triggers, MOTS-c is often described in the literature as an “exercise mimetic”, a label drawn from cell and mouse data.
Some studies have reported that circulating MOTS-c levels fall with age, which is one reason it is investigated in ageing models alongside other mitochondrial research compounds. Human genetics adds a striking extra layer. An East Asian-specific variant in mitochondrial DNA, m.1382A>C, swaps the lysine at position 14 of MOTS-c for glutamine, producing a K14Q form reported to have weaker biological activity.
Because this change occurs naturally, it lets researchers link a single amino acid to measurable traits. In Japanese studies the C allele has been associated with type 2 diabetes risk in men, and a 2022 study tied it to a higher proportion of fast-twitch muscle fibres, with the variant more common in sprint and power athletes than in endurance athletes. A 2024 study of older Korean adults found that men carrying it had greater muscle mass and grip strength. Few peptides offer such a direct bridge between laboratory biology and human population data.
Compound-level reference data. Batch-specific results appear on the Certificate of Analysis.
Work out concentration with the peptide calculatorCrown Peptides MOTS-c is supplied for controlled laboratory research with batch-specific analytical documentation. High-Performance Liquid Chromatography (HPLC) can assess chromatographic purity, while Mass Spectrometry provides molecular information used to support identity verification.
The batch-specific Certificate of Analysis is the definitive source for the exact purity result, identity data and analytical specification of the material supplied.
Researchers working with MOTS-c may also be interested in NAD+, SS-31, Epitalon, 5-Amino-1MQ and L-Carnitine — other compounds studied in cellular energy, metabolism and ageing-related research.
MOTS-c peptide UK from Crown Peptides is a 16-amino-acid mitochondrial-derived peptide encoded within the mitochondrial 12S rRNA region. Its sequence is MRWQEMGYIFYPRKLR, and it is studied as a signalling molecule in energy metabolism. You may also see it written as MOTS c or MOTSc, shorthand for mitochondrial open reading frame of the 12S rRNA type-c.
It was reported in 2015 by Changhan Lee, working in Pinchas Cohen’s group at the University of Southern California. The team went looking for it after the earlier discovery of humanin, a peptide encoded in the mitochondrial 16S rRNA gene, suggested that mitochondrial DNA might hide other short coding sequences.
No. It comes from a short open reading frame within mitochondrial DNA, tucked inside the gene for 12S ribosomal RNA. Almost every protein in a human cell is encoded in the nucleus, which is what makes MOTS-c and its relatives so unusual.
It belongs to the mitochondrial-derived peptides, a small class that provides evidence for mitochondria sending signals to other parts of the cell, including the nucleus, rather than simply producing energy.
The original 2015 study identified skeletal muscle as the peptide’s main target tissue, and muscle is where AMPK-driven glucose handling matters most for whole-body metabolism. Later work added exercise to the picture, showing MOTS-c rising in human muscle after activity and shaping how mouse myoblasts cope with metabolic stress, so energy metabolism, ageing and physical-capacity research all tend to meet in muscle.
Exercise raises MOTS-c in human muscle and blood, and in mice the peptide activates AMPK and improves physical performance, overlapping with the signalling that exercise itself sets off. The nickname comes from that overlap in cell and animal studies.
They work at different levels. MOTS-c is a peptide encoded by mitochondrial DNA and studied as a signalling molecule, while NAD+ is a coenzyme that takes part in energy metabolism inside every cell. See NAD+ vs MOTS-c for the full comparison.
Position 14 is one of the four positively charged residues in MOTS-c. In the East Asian m.1382A>C variant, that lysine becomes an uncharged glutamine, and the resulting K14Q peptide has been reported to be less biologically active. A single swap at one site changing activity suggests the basic C-terminal stretch, PRKLR, matters to how the peptide works.
In more than one place, which is part of its appeal. It is made from mitochondrial DNA, acts on the folate cycle and AMPK in the surrounding cytoplasm, and under metabolic stress moves into the nucleus to influence gene expression. It has also been measured in blood, so researchers study it both inside cells and as a circulating factor.
Cultured cells, including skeletal-muscle myoblasts, carry much of the mechanistic work. Mouse studies cover high-fat diets, insulin resistance, ageing and physical performance across young, middle-aged and old animals. Human data are mostly observational: MOTS-c levels in blood and muscle, the response to exercise, and genetic studies of the K14Q variant.
All three are used in metabolic research, but at different points. L-Carnitine carries fatty acids into mitochondria to be burned, 5-Amino-1MQ is a small molecule that blocks the enzyme NNMT, and MOTS-c is a peptide signal acting through AMPK. Together they let a study look at fuel transport, enzyme activity and signalling side by side.
MOTS-c has methionines at positions 1 and 6, and methionine is the residue most prone to oxidation. Each oxidised methionine adds 16 Da, so in a mass spectrum oxidation shows up as extra peaks 16 or 32 Da above the expected mass of about 2174.6 g/mol (monoisotopic around 2173.1 Da). With four basic residues plus the free N-terminus, the intact peptide itself usually appears as multiply charged ions, such as the triply charged ion near m/z 725.4 and the quadruply charged ion near m/z 544.3. Each batch’s results are published on the Lab Reports page. The peptide also contains light-sensitive tryptophan.
That is why MOTS-c is supplied as a white lyophilised (freeze-dried) powder in a sealed glass vial, and why unopened vials should be kept at -20°C, away from heat and light. See the storage guide for detail.
For cell-culture work and pilot experiments, the 10mg vial keeps material fresh and limits how often a vial is opened. Mouse studies and longer exercise or ageing protocols get through more material, which is where the 40mg vial comes into its own. Multi-vial packs of five or ten are also available at a lower price per vial.
Every batch is published openly — identity, purity and batch number, with no account needed.
Supplied for laboratory research purposes only — not for human consumption or for medical, veterinary or diagnostic use.
Each batch undergoes internal analytical verification using chromatographic and spectrometric methods prior to lyophilisation.
• HPLC Analysis
• Mass Spectrometry Confirmation
• Batch Traceability
By purchasing this product you confirm that you are a qualified researcher and that this compound will be used exclusively for laboratory research purposes.
This product is not intended for diagnostic or therapeutic use.
Any human or medical use is strictly prohibited.
Store in a cool, dry, secure and sterile environment away from any unauthorised persons or children.
Disclaimer: All products are sold strictly for laboratory research purposes only. Not for human or veterinary use, consumption, therapeutic, or diagnostic application. None of our products are medicines, and none are presented as such. By purchasing, you confirm you are a qualified professional and legally permitted to handle these materials in compliance with all applicable laws and regulations. Misuse, resale for unauthorised purposes, or unlawful application is strictly prohibited. Crown Peptides UK disclaims all liability for improper use, handling, or regulatory non-compliance.